RxDoctor Payments Data

Kimberly Johnson, NP

Adult Health · Chula Vista, CANPI 1477024370

Payments from drug & device makers

$3,337in general payments, 2019–2025

Across 73 payments — averaging $45.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$1K
  • Boston Scientific$1K
  • Abbott$276
  • Astellas Pharma US Inc$222
  • Novo Nordisk$162
  • Akebia Therapeutics Inc$105
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$3,13294%
  • Education$2056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,337 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$43,234
Medicare patients
230
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$244,231
EntrestoSacubitril/Valsartan41$65,281
XareltoRivaroxaban45$51,025
Repatha SureclickEvolocumab52$32,207
Metoprolol Succinate228$4,280
Rosuvastatin Calcium115$3,145
Atorvastatin Calcium159$3,025
Ezetimibe86$3,008
Losartan Potassium200$2,757
Valsartan78$2,487
Amlodipine Besylate267$2,399
Nifedipine ErNifedipine68$2,104
Ranolazine ErRanolazine11$1,389
Carvedilol104$969
Spironolactone78$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18$65,28141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.

Other adult health in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →